These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 24075705)

  • 1. [Risk-sharing agreements: choice of study design and assessment criteria].
    Launois R; Ethgen O
    Ann Pharm Fr; 2013 Sep; 71(5):346-57. PubMed ID: 24075705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Conditional pricing for innovative medicines in France: stop telling about risk-sharing!].
    Megerlin F
    Ann Pharm Fr; 2013 Sep; 71(5):291-301. PubMed ID: 24075700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Innovative medicines and market access agreements].
    Toumi M; Zard J; Duvillard R; Jommi C
    Ann Pharm Fr; 2013 Sep; 71(5):302-25. PubMed ID: 24075701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].
    Hammerman A; Greenberg D
    Harefuah; 2012 Jun; 151(6):364-7, 376. PubMed ID: 22991869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
    Towse A; Garrison LP
    Pharmacoeconomics; 2010; 28(2):93-102. PubMed ID: 20085386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Innovative agreements with the pharmaceutical industry: "pay for performance"].
    Badia X; Prior M
    Farm Hosp; 2010; 34(2):53-5. PubMed ID: 20207566
    [No Abstract]   [Full Text] [Related]  

  • 8. [Innovative patient access schemes for the adoption of new technology: risk-sharing agreements].
    Espín J; Oliva J; Rodríguez-Barrios JM
    Gac Sanit; 2010; 24(6):491-7. PubMed ID: 21074292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits.
    Zaric GS; Xie B
    Value Health; 2009; 12(5):838-45. PubMed ID: 19490563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry.
    Barros PP
    Health Econ; 2011 Apr; 20(4):461-70. PubMed ID: 21394816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Contracts including performance and management of uncertainty].
    Duru G; Garassus P; Auray JP
    Ann Pharm Fr; 2013 Sep; 71(5):338-45. PubMed ID: 24075704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel.
    Triki N; Ash N; Porath A; Birnbaum Y; Greenberg D; Hammerman A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):749-753. PubMed ID: 31825682
    [No Abstract]   [Full Text] [Related]  

  • 13. USING CLAIMS DATA FOR EVIDENCE GENERATION IN MANAGED ENTRY AGREEMENTS.
    Brandes A; Schwarzkopf L; Rogowski WH
    Int J Technol Assess Health Care; 2016 Jan; 32(1-2):69-77. PubMed ID: 26975757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement.
    Neumann PJ; Chambers JD; Simon F; Meckley LM
    Health Aff (Millwood); 2011 Dec; 30(12):2329-37. PubMed ID: 22147861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk sharing agreements: what lessons from Italy?
    Garattini L; Casadei G
    Int J Technol Assess Health Care; 2011 Apr; 27(2):169-72. PubMed ID: 21429288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current performance-linked and risk sharing agreement scene in the Spanish region of Catalonia.
    Darbà J; Ascanio M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):743-748. PubMed ID: 30821532
    [No Abstract]   [Full Text] [Related]  

  • 17. [Toward a conditional price for medicine?].
    Baseilhac E
    Ann Pharm Fr; 2013 Sep; 71(5):330-7. PubMed ID: 24075703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach.
    Antonanzas F; Juarez-Castello C; Rodriguez-Ibeas R
    Health Econ Policy Law; 2011 Jul; 6(3):391-403. PubMed ID: 21338542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medico-economic evaluation of health products in the context of the Social Security Financing Act for 2012.
    Dervaux B; Baseilhac E; Fagon JY; ; Ameye V; Angot P; Audry A; Becquemont L; Borel T; Cazeneuve B; Courtois J; Detournay B; Favre P; Granger M; Josseran A; Lassale C; Louvet O; Pinson J; de Pouvourville G; Rochaix L; Rumeau-Pichon C; de Saab R; Schwarzinger M; Sun A
    Therapie; 2013; 68(4):253-63. PubMed ID: 23981264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-sharing agreements for innovative drugs: a new solution to old problems?
    de Pouvourville G
    Eur J Health Econ; 2006 Sep; 7(3):155-7. PubMed ID: 16912890
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.